Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03899792 · ClinicalTrials.gov registry record · Phase 1
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
A Phase 1 study of Soft Tissue Sarcoma and Papillary Thyroid Cancer, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 20
- Study locations
NCT03899792 is a Phase 1 study of Soft Tissue Sarcoma and Papillary Thyroid Cancer that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 36 participants, below the 78-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (54% lower). The trial reports 20 study locations across 18 states.
The verdict
NCT03899792, a Phase 1 study of Soft Tissue Sarcoma and Papillary Thyroid Cancer, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor.
Conditions Studied
Interventions
- DRUG Selpercatinib
Study Locations (20)
Texas
- University of Texas Southwestern Medical Center at Dallas - Dallas
- Texas Childrens Hospital - Houston
Other
- Rigshospitalet - Copenhagen
- Gustave Roussy - Villejuif
California
- Childrens Hospital of Los Angeles - Los Angeles
Colorado
- The Children's Hospital for Cancer and Blood Disorders - Aurora
Florida
- Nemours Children's Health - Orlando
Massachusetts
- Dana-Farber Cancer Institute - Boston
Minnesota
- University of Minnesota Hospital - Minneapolis
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2019-06-13 |
| Est. Completion | 2029-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03899792
The ClinicalTrials.gov registry entry for NCT03899792 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 78-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (54% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Soft Tissue Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which Selpercatinib is the first listed.
NCT03899792 reports 20 study locations spanning 18 distinct geographic areas - top geographies include Texas, Other, California.
Frequently Asked Questions
What is clinical trial NCT03899792 about?
NCT03899792 is a clinical study titled "A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors". This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor.
What is the current status of trial NCT03899792?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2019-06-13. Estimated completion is 2029-05.
What conditions does trial NCT03899792 study?
This clinical trial studies the following conditions: Soft Tissue Sarcoma, Papillary Thyroid Cancer, Medullary Thyroid Cancer, Infantile Fibrosarcoma, Infantile Myofibromatosis.
What interventions are being tested in trial NCT03899792?
The interventions under investigation include: Selpercatinib (DRUG).
Who is sponsoring clinical trial NCT03899792?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03899792 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Soft Tissue Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
RECRUITING · Phase 1
-
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
RECRUITING · Phase 1
-
A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma
RECRUITING · Phase 1
-
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
RECRUITING · Phase 1
-
Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.